Rationale: Unlike conventional dendritic cells, plasmacytoid DCs (PDC) are poor in antigen presentation and critical for type I interferon response. Though proposed to be present in human atherosclerotic lesions, their role in atherosclerosis remains elusive. Objective: To investigate the role of PDC in atherosclerosis. Methods and Results: We show that PDC are scarcely present in human atherosclerotic lesions and almost absent in mouse plaques. Surprisingly, PDC depletion by 120G8 mAb administration was seen to promote plaque T-cell accumulation and exacerbate lesion development and progression in LDLr ؊/؊ mice. Res. 2011;109:1387-1395.) 
P lasmacytoid dendritic cells (PDC) are a subset of dendritic cells derived from both myeloid and lymphoid precursors in bone marrow and constitute only 0.1-0.5% of the total leukocyte pool in blood and peripheral lymphoid tissue. As the main type I interferon (IFN)-producing cells, PDC have a critical role in detection of and host defense against bacterial and viral infection but also in sensing RNA/DNA and immune complexes. On stimulation, PDC produce large amounts of type I interferons (IFN-␣, IFN-␤, IFN-, and IFN-) in a toll-like receptor (TLR) 7-and 9-dependent manner, thereby inducing effector T-cell and natural killer (NK) cell activation and linking innate and adaptive immunity. 1 PDC differ from conventional dendritic cells (CDC) in that they are poor T-cell activators due to low expression of major histocompatibility complex class II and costimulatory molecules. 2, 3 The presence of PDC in human atherosclerotic lesions has been documented in 1995 4 and was subsequently confirmed by Weyand et al. 5 PDC (CD4 ϩ CD45RA ϩ IL-3␣(CD123) ϩ ILT3 ϩ ILT1 -CD11 -) were reported to be expressed in the shoulder region of human plaques, where they are believed to regulate T-cell function, even in the absence of antigen recognition. CpG induced IFN-␣ release by PDC effected a 10-fold upregulation of tumor necrosis factor-related apoptosisinducing ligand expression on CD4 ϩ T-cell surface, thereby promoting vascular smooth muscle cell (VSMC) and endothelial cell (EC) apoptosis, processes that are generally deemed deleterious for plaque stability. However, these in vitro data leave unaddressed whether PDC are instrumental in plaque destabilization in vivo.
Whereas viral infection associated acute PDC activation results in massive type I IFN release, chronic activation of PDC in the absence of infection was reported to cause severe autoimmune diseases. For instance, in experimental autoimmune encephalomyelitis, PDC were shown to exert overt pathogenic activity, mainly by enhancing T helper 17 (Th17)dependent immune responses. 6 In patients with systemic lupus erythematosus, PDC activity and IFN-␣/␤ release correlated with disease activity and severity. 7, 8 Conversely, evidence is culminating that immature and alternatively activated PDC have the capacity to dampen chronic lowgrade inflammation and autoimmune diseases, including diabetes type I, asthma, and transplant rejection, possibly by suppressing CD8 ϩ effector T cell and inducing CD4 ϩ CD25 ϩ regulatory T-cell (Treg) function by the release of tolerogenic molecules such as indoleamine 2,3-dioxygenase (IDO) or programmed death-ligand 1 (PD-L1). 9 -13 Altogether, these observations show that PDC are very plastic cells with the capacity to produce high levels of type I IFN and activate the adaptive immune system in infection on one hand and to regulate inflammation by inhibiting effector T-cell and inducing regulatory T-cell responses on the other hand.
In the present study, we addressed the actual role of PDC in atherosclerosis by a loss-of-function approach, providing evidence for an IDO-dependent, T-cell-suppressive activity of PDC in human and mouse atherosclerosis.
Methods
An expanded Methods section is available in the Data Supplement at http://circres.ahajournals.org.
Atherosclerosis Induction and PDC Depletion in Mice
Female LDLr Ϫ/Ϫ mice, obtained from The Jackson Laboratory and backcrossed at least 11 times to C57Bl/6, were placed on high-fat diet containing 0.25% cholesterol (Special Diets Services, Witham, Essex, UK). Two weeks later, atherosclerotic lesions were induced in the carotid artery by bilateral placement of semiconstrictive collars. To study effects of PDC depletion on atherosclerosis development, a PDC-depleting antibody, 120G8 (250 g per mouse per injection, Bioceros, Utrecht, The Netherlands), was administered intraperitoneally 4 times per week for 3.5 weeks starting at the time of collar placement (nϭ19), after which mice were euthanized. From these mice, also the aortic root was analyzed to study effects of PDC depletion on natural atherosclerosis development. To study effects of PDC depletion on progression of atherosclerosis, 120G8 (250 g per mouse per injection, Bioceros, Utrecht, The Netherlands) was administered intraperitoneally 4 times per week for 3 weeks, starting at 4 weeks after collar placement, once initial lesions had formed (nϭ17). As control antibody, an isotype control (GL113) was used. All animal work was approved by the regulatory authority of Maastricht University and performed in compliance with the Dutch government guidelines.
In Vivo Proliferation Assays
LDLr Ϫ/Ϫ mice on a high-fat diet treated either with 120G8 or GL113 received intraperitoneal injections of BrdU (0.8 mg/d) for 5 consecutive days. BrdU incorporation in CD4 ϩ and CD8 ϩ T cells was assessed using a FITC BrdU flow kit (BD) according to the manufacturer's instructions. Cells were analyzed using FACS CANTO II.
LDLr Ϫ/Ϫ recipient mice on a high-fat diet received CFSE-labeled purified ovalbumin (OVA)-specific OT-1/CD45.1 or OT-2/CD90.1 cells together with nontransgenic purified CD8 ϩ /CD90.1 or CD4 ϩ / CD45.1 T cells that served as an internal control. The next day, mice received intravenous irradiated (1500 rad) Kb Ϫ/Ϫ -actmOVA or C3H-actmOVA cells. Three days later, OT-1/CD90.1 and OT-2/ CD45.1 proliferation and expansion were determined, based on CFSE dilution and the ratio of OT-1/CD45.1 to CD90.1 control CD8 ϩ T cells and OT-2/CD90.1 to CD45.1 control CD4 ϩ T cells. In parallel, splenocytes were restimulated with OVA 257-264 or OVA 323-339 peptide (A&A Labs, San Diego, CA) in the presence of Brefeldin A for 5 hours. Surface staining for CD8/CD4 (BD) and CD45.1/CD90.1 (eBioscience) was performed.
PDC-T-Cell Coculture
PDC were isolated from spleens of Bl6 FLt3L-treated, high-fat diet fed LDLr Ϫ/Ϫ mice, using PDCA-1 microbeads (Miltenyi). Splenic CD3 ϩ T cells from PDC-depleted LDLr Ϫ/Ϫ mice on a high-fat diet were isolated after staining with biotinylated CD4 (Biolegend) and CD8 (Biolegend) antibodies, using a biotin isolation kit (Miltenyi). PDC and CD3 ϩ T cells were cocultured for 3 days at a 1:6 ratio in the presence or absence of 1-MT (Sigma Aldrich, 100 mol/L) or anti-PD-L1 (20 g/mL, Bioceros). CD3 ϩ T-cell proliferation was assessed by 3[H]-thymidine incorporation and plotted as relative proliferation index, defined as the ratio of T-cell proliferation in the presence and absence of PDC. In parallel cultures, purified CD4 ϩ T cells were CFSE-labeled before stimulation, and proliferation was determined by flow cytometry.
Human Atherosclerotic Plaque Analysis
Human atherosclerotic lesions were isolated from carotid endarterectomy patients and graded for progression stage according to Virmani et al. 14 All human work was approved by the Ethics Committee of the University Hospital Maastricht. Written informed consent for participation in the study was obtained from all individuals.
Statistical Analysis
Data are expressed as meanϮSEM and are considered statistically significant at PϽ0.05.
Results

PDC Are Scarce in Human and Mouse Atherosclerotic Lesions
Concordant with previous observations, 5 CD123 ϩ PDC were seen to be present in human atherosclerotic lesions, and their presence increases with plaque progression (PϽ0.05) ( Figure  1A ). Of note, CD123-stained cells were found to show considerable colocalization with macrophages ( Figure 1B ) and VSMC ( Figure 1C ), supporting earlier findings from van Vré et al showing that CD123 is not a specific marker for human PDC. 15 Next, we considered BDCA-4 as a more selective human PDC marker. 16 Flow cytometry on human whole blood samples confirmed the high specificity of this marker for human PDC, as it was virtually absent on circulating monocyte, B-cell, T-cell, and granulocyte subsets (Online Figure I, A) . Surprisingly, BDCA-4 ϩ staining revealed the scanty presence of PDC in human plaques; moreover, BDCA-4 ϩ cell expression did not differ between stable and unstable advanced atherosclerotic lesions ( 
Effective and Selective Depletion of PDC in Mice by 120G8 Antibody Treatment
Next, we addressed the specificity of PDC depletion by 120G8 mAb, which recognizes PDCA-1 (also referred to as bone marrow stromal cell antigen 2 [BST2]), a marker specifically expressed on mouse PDC. 120G8 significantly depleted (Ͼ90%) PDC numbers in blood and spleen (PϽ0.05) ( Figure   2A ). PDC repopulation started 24 hours after a single 120G8 administration, and full recovery was obtained after 72 hours (Online Figure II, A) , necessitating a 120G8 dose regimen once every 2 days for effective and persistent PDC depletion. It has been reported that in vitro PDCA-1 expression is upregulated at the mRNA level in other cell types in response to viral infection or exposure to inflammatory stimuli, which theoretically could thwart the depletion specificity. 17 In our study, 120G8 treatment affected neither CDC ( Figure 2B ) nor B-cell numbers ( Figure 2C ). Also, monocyte and granulocyte levels were unchanged (Online Figure II , B and C). Moreover, assessment of PDCA-1 expression by flow cytometry showed that in high-fat diet-fed LDLr Ϫ/Ϫ mice, PDCA-1 expression is completely restricted to PDC ( Figure 2D ). These data demonstrate that in our mouse model of atherosclerosis, PDC depletion by 120G8 mAb was effective and 
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specific. To investigate whether prolonged antibody administration by itself could modulate immune responses, we compared the T-cell activation status between GL113-and PBS-treated mice and did not find a difference in the number of CD44 high T cells (Online Figure II, D) . At a functional level, 120G8 treatment almost abrogated CpG-induced PDC activation in vivo, as judged by the 6-fold attenuated induction in plasma IFN-␣ release on CpG injection in 120G8 treated versus control mice (PϽ0.05; Figure 2E ). Although PDC activity and TLR 7/9 function appear to be intact, under conditions of hyperlipidemia, baseline plasma IFN-␣ levels remained unchanged after PDC depletion, both in the plaque initiation and progression study. This suggests that an atherogenic stimulus per se does not increase IFN-␣ release by peripheral PDCs and/or that PDC are under these conditions not the major source of circulating IFN-␣.
Depletion of PDC Accelerates Atherosclerosis in LDLr ؊/؊ Mice
To address the role of PDC in atherosclerosis, we examined lesion development and progression in LDLr Ϫ/Ϫ mice fed a high-fat diet. For plaque initiation, 120G8 treatment was started at the time of collar placement, whereas for plaque progression, it was started at week 4 after collar placement, once initial lesions had formed. The 120G8 treatment did not affect body weight, nor did it lead to overt pathogenic responses;120G8 treatment tended to decrease plasma cholesterol levels initially (1384Ϯ78.53 versus 1126Ϯ46.28 pg/mL in control and 120G8-treated mice, respectively), but this effect was blunted at later stages of plaque development (1097Ϯ44.83 versus 1231Ϯ72.31 pg/mL in control and 120G8treated mice, respectively) (Table) . To our surprise, atherosclerosis considerably deteriorated after PDC depletion. Plaque volume was 2-fold increased in the plaque initiation study (1.4ϫ10 7 Ϯ2.6ϫ10 6 versus 2.7ϫ10 7 Ϯ4.7ϫ10 6 m 3 in control and 120G8-treated mice, respectively) (PϽ0.05) ( Figure 3A) , whereas we observed a 3-fold increase in plaque progression compared with plaques at baseline (1.4ϫ10 Ϯ2.5ϫ10 6 versus 5.4ϫ10 7 Ϯ7.2ϫ10 6 m 3 in control baseline and 120G8-treated mice, respectively) (PϽ0.0005) versus only 2-fold for the GL113 Ab-treated mice (1.4ϫ10 7 Ϯ2.5ϫ10 6 versus 3.3ϫ10 7 Ϯ 7.5ϫ10 6 m 3 in control baseline and GL113-treated mice, respectively) (PϽ0.05) ( Figure 3B ). Likewise, PDC depletion induced a more unstable plaque phenotype in the progression study, characterized by necrotic core expansion ( Figure 3C ) and diminished cap VSMC content ( Figure 3D ). There was no difference in plaque collagen content (data not shown). In addition to the carotid artery, we also examined atherosclerosis development in the aortic root, showing an essentially similar aggravation of lesion formation after PDC depletion (PϽ0.05; Figure 3E ). Thus, our data point to an unexpected protective role of PDC in atherosclerosis, which is in contrast to the prevailing notion that PDC might promote atherosclerosis by activating T cells in a type I IFN-dependent manner. 5, 18 Moreover, given the fact that atherosclerotic lesions are virtually devoid of PDC, they probably exert their atheroprotective effect by modulating immune responses in the periphery and/or adventitia.
PDC Exert Their Atheroprotective Effect by Regulating CD4 ؉ T-Cell Proliferation and Function in Lymphoid Tissue
As a next step, we examined effects of PDC depletion on plaque composition to address the potential mechanisms responsible for the protective effects of PDC in atherosclerosis. We found that PDC depletion led to an increase in lesional T-cell accumulation (PϽ0.05; Figure 4A and Online Figure III, A) . The scarce presence of PDC in mouse atherosclerotic lesions suggests that the increased T-cell infiltration into the lesions probably reflects peripheral modulation of T-cell function. Indeed, blood and spleen T-cell content was increased in PDC-depleted mice (PϽ0.05; Figure  4B ), suggesting that PDC interfere with T-cell homeostasis. As PDC have been reported to induce regulatory T-cell GL113 baseline group represents plaque formation at start of antibody treatment. Right carotid artery was stained with hematoxylin and eosin and atherosclerotic lesion burden was analyzed (plaque volume, m 3 ). C, Necrotic core area is represented as the percentage of lipid core area over plaque area. Data are represented for the plaque progression study. D, ASMA content is presented as the percentage of aSMA ϩ positive cells per plaque area. Data are represented for the plaque progression study. E, Effects of PDC depletion on atherosclerosis development in the aortic root (GL113-treated, nϭ9, versus 120G8-treated, nϭ10 mice). The aortic root was stained with hematoxylin and eosin to analyze the extent of atherosclerosis (plaque area, m 2 ). expansion, 11, 19 we investigated whether the increase in plaque CD3 ϩ T-cell content is owing to decreased Treg numbers or function and an associated failure to control T-cell responses. However, we did not observe a difference in blood and spleen Treg numbers between 120G8-and GL113-treated LDLr Ϫ/Ϫ mice (Online Figure III, B) . In keeping, IL-10 plasma levels did not differ as well (Online Figure III, C) . To address whether the increase in T cells resulted from increased proliferation or survival, we examined T-cell proliferation in vivo. Spleens of PDC-depleted mice were enriched in BrdU ϩ CD4 ϩ (PϽ0.05; Figure 4C ) but not CD8 ϩ T cells (Online Figure III, D) . Moreover, T-cell proliferation appeared to be antigen-dependent in that OVA challenge led to augmented proliferation of OT-2 CD4 ϩ T cells (PϽ0.05; Figure 4D ) but not OT-1 CD8 ϩ T cells (Online Figure III, E) in PDCdepleted versus nondepleted mice. In addition, these findings also show that the increased proliferation is not due to intrinsic T-cell effects, as both innate and administered T-cell proliferation was increased, but to changes in the environment in PDC-depleted mice. In parallel to increased T-cell proliferation, IFN-␥ (PϽ0.0005; Figure 4E ) as well as IL-6 and MCP-1 plasma levels (Online Figure III, F) were seen to be increased after PDC depletion. FACS-sorted CD3 ϩ T cells (purity 95%) from spleens of PDC-depleted LDLr Ϫ/Ϫ mice tended to have increased IFN-␥ expression (Pϭ0.07; Figure  4F ). In addition, CD3 ϩ T cells isolated from atherosclerotic (high-fat diet-fed) LDLr Ϫ/Ϫ mice expressed higher levels of GATA-3 (Th2 marker) as well as of t-bet (Th1 marker) compared with T cells isolated from nonatherosclerotic mice (chow diet-fed) mice (Online Figure III, G) . PDC depletion abrogated this effect for GATA-3 but not t-bet, suggesting that PDC might help to dampen the high-fat diet-induced Th1 shift in LDLr Ϫ/Ϫ mice. Overall, these data further substantiate a tolerogenic activity of PDC under atherogenic conditions, probably by suppressing T-cell proliferation and function.
PDC Suppress CD4 ؉ T-Cell Proliferation in an IDO-Dependent Manner
To address the underlying mechanism for the T-cell suppressive capacity of PDC in atherosclerosis, we compared the expression of known key regulators of PDC tolerogenicity, such as IDO, IL-10, PD-L1, and inducible costimulatorligand (ICOS-L), by PDC isolated from chow (nonatherosclerotic mice) versus high-fat diet-fed (atherosclerotic mice) LDLr Ϫ/Ϫ mice (purity, 98.3%). Expression of PD-L1 and IDO (PϽ0.05; Figure 5A ) but not IL-10 and ICOS-L (data not shown), was significantly elevated in PDC from high-fat diet-fed versus chow-fed mice. Importantly, CD3 ϩ T cells isolated from spleen of PDC-depleted atherosclerotic mice, cocultured with PDC in the presence of 1-methyl-trypthophan (1-MT), an IDO blocker, but not anti-PD-L1, displayed markedly induced T-cell proliferation (PϽ0.05; Figure 5B ), suggesting that PDC suppress T-cell proliferation in an IDO-dependent manner. The 1-MT induced CD4 ϩ T-cell mitogenic response was confirmed by flow cytometry ( Figure  5C) , showing a similar increment in CD4 ϩ T-cell proliferation after coculture with PDC in the presence of 1-MT. Baseline levels of IFN-␣ in plasma of high-fat diet-fed versus chow-fed LDLr Ϫ/Ϫ mice were unaltered ( Figure 5D ), as well as IFN-␣ expression by PDC ( Figure 5E ), firmly establishing that in mice, proatherogenic conditions per se do not promote IFN-␣ release and immunogenic activity. Moreover, we extend these findings to the human context, as in LDLr Ϫ/Ϫ mice, IFN-␣ plasma levels were also seen to be unchanged ( Figure 5F ) and IFN-␣ expression by PDC even significantly lowered in atherosclerotic patients versus healthy controls (PϽ0.05; Figure 5G ). Altogether, our data indicate that both in mice and humans, conditions of chronic atherosclerosis do not trigger PDC immunogenic activity, IFN-␣ release, and ensuing T-cell activation and proliferation. Rather, this milieu may even consolidate PDC's innate tolerogenic capacity to suppress T-cell proliferation. 20
Discussion
In the present study, we are the first to demonstrate a contributory role for PDC in atherosclerosis. Despite the scarce presence of PDC in mouse atherosclerotic lesions, depletion of PDC in LDLr Ϫ/Ϫ mice by 120G8 mAb aggravated atherosclerosis development and progression. Lesions of PDC-depleted mice were characterized by increased T-cell accumulation and a more unstable plaque phenotype, which, as we show, probably is linked to a deficiency in PDCassociated, epitope-specific dampening of T-cell response.
We demonstrate selective and almost complete PDC depletion by the use of 120G8 mAb in LDLr Ϫ/Ϫ mice. PDCA-1 expression was exclusively restricted to the PDC population, and no other leukocyte subsets other than PDC were depleted. These findings confirm previous reports that highlight the specificity of the 120G8 mAb, all showing selective depletion of PDC in blood, bone marrow, lymph node, thymus, and nonlymphoid organs of C57Bl6 mice but not of CD4/CD8 T cells, DX5 ϩ NK, and CD19 ϩ B cells. [21] [22] [23] [24] Alternative PDC ablation or depletion models currently available such as IKAROS and IRF8 (mutant) all have major effects on non-PDC subsets, whereas the CD11c.CRE x E22 f/and the BDCA-2.hDTR mice are interesting new models for future ablation studies.
Our data point to an unexpected atheroprotective activity of PDC, which is in contrast to previous findings pointing toward a proatherogenic function. 5 This notion was largely based on guilt by association, in that (1) plaques were seen to express CD123 ϩ and IFN-␣ ϩ cells, in particular when progressed to an unstable phenotype, (2) CpG induced PDC activation in vitro led to type I IFN release, and (3) type I IFN were recently reported to contribute to atherosclerosis in ApoE Ϫ/Ϫ and LDLr Ϫ/Ϫ mice by stimulating macrophage recruitment. 18 The data presented in this study justify a minor adjustment of this assumption. First, unlike BDCA-4, CD123 staining may not be entirely reflective of the plaque's PDC content because macrophages and VSMCs appear to express this marker as well and as CD123 ϩ cells often lack characteristic plasmacytoid morphology. This observation concurs with recent findings by van Vré et al, showing that CD123 is not a specific PDC marker staining also for endothelial cells in human atherosclerotic lesions. 15 As a result, the actual plaque PDC content may not only be lower than originally envisioned but also does not markedly increase with progression of disease. This also implies that PDC effects may be precipitated primarily in the periphery rather than within the plaque itself. Second, we show that PDC are not the prime source of plasma IFN-␣ at baseline and that IFN-␣ release by PDC into the circulation is boosted by CpG treatment but not by atherogenic conditions. Apparently, atherogenic stimuli per se do not induce PDC activation. Moreover, in atherosclerotic mice, circulating IFN-␣ originates from cell types other than PDC but may be derived from macrophages. Third, we failed to demonstrate progressively increased expression of IFN-␣ (by microarray or real-time PCR analysis) by circulating PDC from atherosclerotic mice and by human PDC from patients with stable versus unstable disease and by unstable versus stable endarterectomy lesions, confirming that in chronic inflammatory processes such as atherosclerosis TLR7/9 activation of PDC is not very prominent. Collectively, our data indicate that PDC exert their atheroprotective effect primarily by modulating extravascular immune responses.
Our studies also provide a plausible mechanism by which PDC suppress CD4 ϩ T-cell proliferation under conditions of atherosclerosis. PDC isolated from spleens from atherosclerotic mice had a 2-fold increase in expression of tolerogenic molecules IDO and PD-L1 compared with PDC isolated from nonatherosclerotic mice. IDO is an intracellular tryptophan catabolizing enzyme that has been attributed suppressive activity on CDCs and stimulatory activity on Tregs. 25 PD-L1 is an inhibitory costimulatory molecule that interacts with programmed death-1 (PD-1) on CD8 ϩ T cells to suppress their viability and activity. 26 Moreover, coculture of PDC with T cells in the presence of 1-MT, an IDO blocker, but not anti-PD-L1, showed increased T-cell proliferation, suggesting that PDC suppress T-cell proliferation in an IDO-dependent manner. These observations correspond with previous reports in which PDC were shown to induce tolerance in other low-grade chronic inflammatory and autoimmune diseases. 9, 10, [25] [26] [27] The tolerogenic function of PDC was seen to depend on cytokine/ligand activation. For instance, B7-1 (CD80) engagement by Cytotoxic T-lymphocyte Antigen-4 (CTLA-4Ig), that of CD200R1 by CD200Ig, and B7-1/B7-2 (CD80/CD86) by CD28Ig all have been shown to be able to induce the release of IDO by PDC, leading to the suppression of T cells. 28 It remains to be established which activation pathway is involved in atherosclerosis. Thus, in analogy, during atherosclerosis, PDC not only maintain their immature tolerogenic state but even invigorate their inborn dampening activity so that they can control T-cell activity. It remains to be established whether the same holds for brief episodes of fulminant plaque inflammation (acute myocardial infarction).
In conclusion, this report is the first to unveil a protective role for PDC in an established mouse model of atherosclerosis, throughout disease progression. Given the virtual absence of PDC in the plaque itself, PDC probably exert their activity extravascularly by dampening T-cell proliferation and function in an IDO-dependent manner. Although these findings identify PDC as an interesting new target for therapeutic intervention studies, they warrant further study to elucidate the actual pathways underlying the augmented tolerogenic activity of PDC under conditions of atherosclerosis.
